Skip to main content
. 2021 Nov 7;49(1):95–105. doi: 10.1111/1346-8138.16214

FIGURE 3.

FIGURE 3

Treatment sequence by drug class. (a) Tumor necrosis factor (TNF)‐α inhibitors. (b) Interleukin (IL)‐12/23 inhibitor. (c) Anti‐IL‐17 agents. (d) IL‐23p19 inhibitor. Drug classes were: TNF‐α inhibitors = etanercept, adalimumab, and infliximab; IL‐12/23 inhibitor = ustekinumab; anti‐IL‐17 agents = secukinumab, ixekizumab, and brodalumab; and IL‐23p19 inhibitor = guselkumab.